Literature DB >> 19555209

The potential use of Toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents.

Amani Makkouk1, Alexander M Abdelnoor.   

Abstract

Toll-like receptors (TLR) and their ligands are one of the main players in the initiation of innate immunity which precedes, and is required, for the establishment of adaptive immunity. Manipulating the immune response by using TLR agonists or antagonists might be of therapeutic and/or prophylactic value. This review covers; 1-TLR. their natural ligands and ligand - TLR signaling events, 2-TLR against and their use in clinical trials as vaccine adjuvants, and to treat allergy, cancer and infectious diseases, 3-TLR antagonists and their use in clinical trials to treat septic shock and autoimmune diseases. Potential drawbacks related to their potential use as prophylactic and/or therapeutic agents are discussed.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19555209     DOI： 10.1080/08923970902802926

Source DB:  PubMed          Journal:  Immunopharmacol Immunotoxicol        ISSN： 0892-3973            Impact factor:   2.730


  17 in total

1.  Identification of novel synthetic toll-like receptor 2 agonists by high throughput screening.

Authors:  Yue Guan; Katherine Omueti-Ayoade; Sarita K Mutha; Paul J Hergenrother; Richard I Tapping
Journal:  J Biol Chem       Date:  2010-05-26       Impact factor: 5.157

Review 2.  Modulation of γδ T cell responses by TLR ligands.

Authors:  Daniela Wesch; Christian Peters; Hans-Heinrich Oberg; Kathrin Pietschmann; Dieter Kabelitz
Journal:  Cell Mol Life Sci       Date:  2011-05-11       Impact factor: 9.261

3.  Paradoxical decrease in the capture and lymph node delivery of cancer vaccine antigen induced by a TLR4 agonist as visualized by dual-mode imaging.

Authors:  Deepak K Kadayakkara; Michael J Korrer; Jeff W M Bulte; Hyam I Levitsky
Journal:  Cancer Res       Date:  2014-11-11       Impact factor: 12.701

Review 4.  Advances in Infectious Disease Vaccine Adjuvants.

Authors:  Jingyi Fan; Shengbin Jin; Lachlan Gilmartin; Istvan Toth; Waleed M Hussein; Rachel J Stephenson
Journal:  Vaccines (Basel)       Date:  2022-07-13

Review 5.  Immunomodulatory effects of dsRNA and its potential as vaccine adjuvant.

Authors:  Bo Jin; Tao Sun; Xiao-Hong Yu; Chao-Qun Liu; Ying-Xiang Yang; Ping Lu; Shan-Feng Fu; Hui-Bin Qiu; Anthony E T Yeo
Journal:  J Biomed Biotechnol       Date:  2010-07-05

Review 6.  The battle between virus and host: modulation of Toll-like receptor signaling pathways by virus infection.

Authors:  Shin-Ichi Yokota; Tamaki Okabayashi; Nobuhiro Fujii
Journal:  Mediators Inflamm       Date:  2010-06-16       Impact factor: 4.711

7.  Targeted liposomal drug delivery to monocytes and macrophages.

Authors:  Ciara Kelly; Caroline Jefferies; Sally-Ann Cryan
Journal:  J Drug Deliv       Date:  2010-10-26

8.  Type I interferon drives dendritic cell apoptosis via multiple BH3-only proteins following activation by PolyIC in vivo.

Authors:  Silvia A Fuertes Marraco; Clare L Scott; Philippe Bouillet; Annette Ives; Slavica Masina; David Vremec; Elisa S Jansen; Lorraine A O'Reilly; Pascal Schneider; Nicolas Fasel; Ken Shortman; Andreas Strasser; Hans Acha-Orbea
Journal:  PLoS One       Date:  2011-06-02       Impact factor: 3.240

9.  Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis.

Authors:  Rachel A Harry; Amy E Anderson; John D Isaacs; Catharien M U Hilkens
Journal:  Ann Rheum Dis       Date:  2010-06-15       Impact factor: 19.103

Review 10.  Phytochemicals targeting Toll-like receptors 4 (TLR4) in inflammatory bowel disease.

Authors:  Wenbin Dai; Longhai Long; Xiaoqiang Wang; Sen Li; Houping Xu
Journal:  Chin Med       Date:  2022-04-28       Impact factor: 4.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.